Given the fact that zonulin is significantly elevated in atherosclerosis and increase intestinal IP, it’s possible that targeting zonulin using monoclonal antibody or inhibitors maybe a provocatively new way to move forward in CAD prevention and treatment. The gene discussed is HP; the disease is atherosclerosis.